Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations

Fig. 3

Waterfall plot of patients with EGFR-mutated NSCLC treated with initial EGFR-TKIs. The average tumor shrinkage rate relative to baseline in 78 patients with EGFR-mutated NSCLC treated with initial EGFR-TKIs. Re-biopsy samples obtained after the development of acquired resistance to initial EGFR-TKIs revealed that 39 patients had the T790M mutation (red bar) and 39 patients did not have the T790M mutation (blue bar). The median tumor shrinkage rate in these patients indicated a significant association with the emergence of EGFR-T790M (42.7 and 24.0%, respectively, p = 0.001)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us